Enquête épidémiologique Sur la prévalence et le Pronostic de l'Histiocytose Langerhansienne Pulmonaire de l'Adulte en France

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown. This is the first prospective study in the field evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based study included a large cohort of PLCH patients followed for a sufficiently long period to address risk factors of long-term outcomes of PLCH patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \>= 18 years

• Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses

Locations
Other Locations
France
French national reference centre for Histiocytoses
RECRUITING
Paris
Contact Information
Primary
Abdellatif TAZI, MD PhD
abdellatif.tazi@aphp.fr
142499198
Backup
matthieu resche-rigon, MD PhD
matthieu.resche-rigon@u-paris.fr
142499742
Time Frame
Start Date: 2004-01-01
Estimated Completion Date: 2035-12-31
Participants
Target number of participants: 500
Treatments
Pulmonary Langerhans cell histiocytosis (PLCH)
All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov

Similar Clinical Trials